SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting significant retail and institutional interest as investors anticipate major clinical milestones, specifically the upcoming pancreatic cancer data and U.S. trial recruitment results. The community remains highly bullish, frequently discussing the company's strong balance sheet, the potential of its Alpha DaRT platform, and the recent positive analyst sentiment that highlights significant upside from current levels.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing a significant shift in sentiment as investors pivot from pure-play Bitcoin mining to the company's massive 1.4GW high-performance computing expansion. The community is actively debating the impact of the company's capital strategy and potential upcoming deal flow, while traders closely monitor the stock's technical recovery from recent lows amid the broader AI infrastructure demand cycle.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing a surge in momentum and heightened community focus following a series of strategic catalysts, including a multi-year partnership with Anthropic and an expanded compute deal with Meta. Traders are actively debating the stock's potential for a short squeeze as institutional capital flows into AI infrastructure, with many participants viewing the firm as a critical player in the compute arms race.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in retail interest and bullish sentiment as traders analyze the company's strategic positioning within the AI infrastructure stack and speculate on its role in critical data center supply chains. Community discussion is heavily focused on the company's substantial cash-to-value ratio, potential acquisition interest, and the high-conviction bet that its proprietary optical interposer technology will solve major bandwidth bottlenecks for hyperscalers.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently experiencing significant momentum as investors anticipate the upcoming launch of its BlueBird 7 satellite, a pivotal milestone in its efforts to provide direct-to-device cellular broadband. Community sentiment is overwhelmingly bullish, with discussions focused on potential strategic partnerships with tech giants, the scaling of satellite deployment, and the broader institutional shift toward space-based infrastructure as a critical sector for future connectivity.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining attention as a long-standing cultural artifact, with community members emphasizing its origins as the original parody token from 2011 to differentiate it from newer copycat projects. Investors are actively discussing whale accumulation and the potential for a significant breakout, framing the coin as a persistent, inevitable asset rather than a fleeting trend.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is under significant pressure as the weight-loss drug market becomes increasingly competitive with new oral offerings from Eli Lilly, driving concerns about long-term market share and pricing power. While investors remain divided on whether the stock is a deep-value opportunity given its current valuation and pipeline potential, community sentiment is largely frustrated by the stock's persistent downward trend and lack of bullish momentum.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to its recent $4M+ in U.S. government contract wins and the strategic hiring of industry veterans to accelerate its transition from R&D to commercial-scale production. The investment community is intensely focused on the company's progress in wafer-scale semiconductor integration, with significant debate over its potential to supply next-generation sensors for consumer mobile devices and data center optical interconnects.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending due to its $750 million acquisition of DustPhotonics, a strategic move designed to dominate the silicon photonics market and accelerate its expansion into next-generation AI infrastructure. Investors are actively discussing the company's dual-track expertise in copper and optical connectivity, with many highlighting the stock as a key 'picks and shovels' play in the burgeoning AI data center sector.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is surging following an expanded partnership with Oracle to deploy 2.8 gigawatts of fuel cell systems for AI data center infrastructure, validating its role as a key provider of rapid, on-site power solutions. The community is actively discussing the stock's role as a major beneficiary of the AI power supercycle, with many traders closely monitoring for a breakout past recent resistance levels as the company transitions into a critical energy infrastructure player.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Lisata...

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.read more...

Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs

(RTTNews) - Lisata Therapeutics Inc. (LSTA) announced that it has entered into a definitive agreement to be acquired by Kuva Labs Inc., a privately held company. Under the terms of the merger...

Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Feb. 11, 2026 Insiders may stand to...

Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA...

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable...

<ul class="summary-bullets"><li>Lisata and Kuva intend to enter into a definitive purchase agreement before Feb 27.</li><li>Under the deal, Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash.</li><li>Lisata shareholders will also be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.</li></ul>&nbsp;Shares of Lisata Therapeutics, Inc. (LSTA) soared 88% on Wednesday after the company said that it has a buyout offer from privately held Kuva Labs, Inc., valuing the company at up to $6/share.Lisata <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-enters-term-sheet-be-acquired-kuva-labs-400">said</a> that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement whereby Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. In addition, Lisata shareholders will be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.The transaction has been approved by the board of both companies and Lisata and Kiuva intend to enter into a definitive purchase agreement before Feb 27, Lisata said.The $4 upfront purchase price represents a premium of about 85% from the stock’s closing price on Tuesday.<h2 class="st-heading-2">Lisata’s Pipeline</h2>Lisata’s lead product candidate Certepetide is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.In November 2024, Kuva had licensed Certepetide as a targeting and enhanced delivery agent to be used with its NanoMark platform technology. The NanoMark platform enables selective imaging of solid tumors with high contrast and spatial resolution, facilitating faster and more accurate diagnosis and treatment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LSTA stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that they are not selling their shares for below $8.<stembedurl>https://www.stocktwits.com/iNeedMillions/message/642431338</stembedurl>Another wondered if some other company would make a higher bid for Lisata.<stembedurl>https://www.stocktwits.com/Defen/message/642409160</stembedurl><a href="https://stocktwits.com/symbol/LSTA">LSTA stock</a> has gained 4% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-dismisses-rumors-of-1700-layoffs-at-german-gigafactory-report/cmUDDUFR4fV">Tesla Dismisses Rumors Of 1700 Layoffs At German Gigafactory: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lisata Shares Nearly Double On Buyout Offer: Here Are The Details

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.

Equity

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.


All-Cash Buyout Sparks Breakout Move in Biotech Name

Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Lisata Therapeutics Inc

Start of a real move higher

Dead cat - we retest the lows

Show me the results

Software is bouncing hard today. Is this the start of a sustained recovery or just a dead cat bounce before we retest the lows?

LSTA
Lisata Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LSTA News

LSTALisata Therapeutics Inc